BMY – Bristol-Myers Squibb Company
Bristol-Myers Squibb CompanyBMY
$61.48Name : Bristol-Myers Squibb Company
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $125,525,893,120.00
EPSttm : 3.46
Bristol-Myers Squibb Company
$61.48
1.37%$0.83
BMY — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
1.47
Margin Of Safety %
26
Put/Call OI Ratio
0.91
EPS Next Q Diff
1.13
EPS Last/This Y
2.8
EPS This/Next Y
-0.13
Price
60.65
Target Price
62.42
Analyst Recom
2.44
Performance Q
12.09
Upside
-25.8%
Beta
0.28
Ticker: BMY
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-02 | BMY | 62.32 | 0.74 | 0.61 | 597674 |
| 2026-03-04 | BMY | 62.31 | 0.77 | 0.22 | 596457 |
| 2026-03-05 | BMY | 60.74 | 0.76 | 0.60 | 602611 |
| 2026-03-09 | BMY | 60.62 | 0.76 | 0.47 | 607023 |
| 2026-03-10 | BMY | 60.15 | 0.77 | 0.19 | 608031 |
| 2026-03-11 | BMY | 59.96 | 0.76 | 1.04 | 611470 |
| 2026-03-12 | BMY | 58.92 | 0.78 | 0.50 | 626283 |
| 2026-03-17 | BMY | 59.72 | 0.79 | 0.96 | 627213 |
| 2026-03-18 | BMY | 59.37 | 0.79 | 0.38 | 631304 |
| 2026-03-19 | BMY | 58.12 | 0.78 | 0.83 | 637827 |
| 2026-03-20 | BMY | 57.47 | 0.77 | 1.99 | 641441 |
| 2026-03-23 | BMY | 57 | 0.95 | 0.80 | 482297 |
| 2026-03-24 | BMY | 57.38 | 0.95 | 0.74 | 495969 |
| 2026-03-25 | BMY | 58.97 | 0.94 | 0.29 | 500619 |
| 2026-03-26 | BMY | 59.42 | 0.93 | 0.62 | 517393 |
| 2026-03-27 | BMY | 58.51 | 0.92 | 0.76 | 529277 |
| 2026-03-30 | BMY | 59.75 | 0.91 | 0.52 | 521208 |
| 2026-03-31 | BMY | 60.65 | 0.91 | 0.28 | 526551 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-02 | BMY | 62.33 | -19.6 | 3770.5 | 6.25 |
| 2026-03-03 | BMY | 61.24 | -19.5 | 3572.4 | 6.27 |
| 2026-03-04 | BMY | 62.31 | -19.5 | 3985.6 | 6.27 |
| 2026-03-05 | BMY | 60.72 | -19.5 | 3479.0 | 6.27 |
| 2026-03-06 | BMY | 60.28 | -19.5 | 3693.6 | 6.27 |
| 2026-03-09 | BMY | 60.62 | -19.5 | 3843.3 | 6.27 |
| 2026-03-10 | BMY | 60.15 | -19.5 | 3686.4 | 6.27 |
| 2026-03-11 | BMY | 59.97 | -19.5 | 3748.3 | 6.27 |
| 2026-03-12 | BMY | 58.92 | -19.5 | 3573.8 | 6.27 |
| 2026-03-13 | BMY | 59.08 | -19.5 | 3804.3 | 6.27 |
| 2026-03-17 | BMY | 59.72 | -19.5 | 3766.4 | 6.27 |
| 2026-03-18 | BMY | 59.35 | -19.5 | 3710.3 | 6.27 |
| 2026-03-19 | BMY | 58.12 | -19.5 | 4200.9 | 6.27 |
| 2026-03-20 | BMY | 57.46 | -19.5 | 4319.4 | 6.27 |
| 2026-03-23 | BMY | 57.01 | -19.5 | 4355.8 | 6.27 |
| 2026-03-24 | BMY | 57.39 | -19.5 | 4536.0 | 6.27 |
| 2026-03-25 | BMY | 58.96 | -19.5 | 4781.4 | 6.27 |
| 2026-03-26 | BMY | 59.40 | -19.5 | 4558.8 | 6.27 |
| 2026-03-27 | BMY | 58.51 | -19.5 | 4278.2 | 6.27 |
| 2026-03-30 | BMY | 59.75 | -19.5 | 4712.3 | 6.27 |
| 2026-03-31 | BMY | 60.65 | -19.5 | 4649.9 | 6.27 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-02 | BMY | -1.43 | 1.03 | 1.56 |
| 2026-03-03 | BMY | -1.43 | 1.03 | 1.56 |
| 2026-03-04 | BMY | 0.00 | 1.03 | 1.56 |
| 2026-03-05 | BMY | 0.00 | 1.03 | 1.56 |
| 2026-03-06 | BMY | 0.00 | 1.03 | 1.56 |
| 2026-03-09 | BMY | 0.00 | 1.02 | 1.56 |
| 2026-03-10 | BMY | 0.00 | 1.02 | 1.56 |
| 2026-03-11 | BMY | 0.00 | 1.02 | 1.64 |
| 2026-03-12 | BMY | 0.00 | 1.02 | 1.64 |
| 2026-03-13 | BMY | 0.00 | 1.02 | 1.64 |
| 2026-03-17 | BMY | 0.00 | 1.22 | 1.64 |
| 2026-03-18 | BMY | 0.00 | 1.22 | 1.64 |
| 2026-03-19 | BMY | 0.00 | 1.22 | 1.64 |
| 2026-03-20 | BMY | 0.00 | 1.22 | 1.64 |
| 2026-03-23 | BMY | 0.00 | 1.13 | 1.64 |
| 2026-03-24 | BMY | 0.00 | 1.13 | 1.64 |
| 2026-03-25 | BMY | 0.00 | 1.13 | 1.47 |
| 2026-03-26 | BMY | 0.00 | 1.13 | 1.47 |
| 2026-03-27 | BMY | 0.00 | 1.13 | 1.47 |
| 2026-03-30 | BMY | 0.00 | 1.12 | 1.47 |
| 2026-03-31 | BMY | 0.00 | 1.12 | 1.47 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.53
Avg. EPS Est. Current Quarter
1.45
Avg. EPS Est. Next Quarter
1.66
Insider Transactions
Institutional Transactions
1.12
Beta
0.28
Average Sales Estimate Current Quarter
10870
Average Sales Estimate Next Quarter
11898
Fair Value
76.64
Quality Score
86
Growth Score
48
Sentiment Score
83
Actual DrawDown %
25.5
Max Drawdown 5-Year %
-47.7
Target Price
62.42
P/E
17.54
Forward P/E
9.89
PEG
P/S
2.56
P/B
6.68
P/Free Cash Flow
9.62
EPS
3.46
Average EPS Est. Cur. Y
6.27
EPS Next Y. (Est.)
6.14
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
14.64
Relative Volume
0.94
Return on Equity vs Sector %
10.8
Return on Equity vs Industry %
1.6
EPS 1 7Days Diff
EPS 1 30Days Diff
0.04
EBIT Estimation
4649.9
◆
BMY
Healthcare
$60.65
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
57.4
Range 1M
61.5%
Sup Dist
2.4%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
1.8%
EPS NY
-2.1%
52W%
87.8%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+24.3% upside
Upside
+24.3%
Quality
86
MoS
26%
Bristol-Myers Squibb CompanySector: Healthcare
Industry: Drug Manufacturers - General
Employees: 32500
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
BMY
Latest News
—
Caricamento notizie per BMY…
stock quote shares BMY – Bristol-Myers Squibb Company Stock Price stock today
news today BMY – Bristol-Myers Squibb Company stock forecast ,stock prediction 2023 2024 2025
marketwatch BMY – Bristol-Myers Squibb Company yahoo finance google finance
stock history BMY – Bristol-Myers Squibb Company invest stock market
stock prices BMY premarket after hours
ticker BMY fair value insiders trading